431-440 of 625 results
High Court unanimously finds isolated genetic material not patentable
In the culmination of a hard-fought patent dispute the High Court of Australia has unanimously ruled that Myriad Genetics patent claims to isolated nucleic acid coding for the mutant or polymorphic BRCA1 polypeptide are not valid ...
Allens advises M2 Group on major trans-Tasman acquisition
Allens has advised Australian ASX-listed company M2 Group Ltd on its full acquisition of New Zealand's third largest internet service provider for A$245 million. The deal will see M2 Group purchase ...
Allens advises Computer Sciences Corporation on the acquisition of UXC Ltd
Allens has advised global IT services provider, Computer Sciences Corporation (CSC), on the $427.6 million acquisition of UXC Ltd (UXC), Australia's largest publicly-owned IT services company. CSC ...
Allens advises Archer Capital on sale of Healthe Care
Allens has advised Archer Capital on its proposed divestment of private hospital business Healthe Care to China's Luye Medical Group. Healthe Care is Australia's third largest private hospital ...
Dixon Hospitality says cheers to Beer DeLuxe
Allens has advised Dixon Hospitality on its acquisition of the Beer DeLuxe venues in NSW and Victoria. Dixon has acquired six venues including those in the entertainment precincts of King Street ...
Allens advises Public Transport Victoria on myki re-tendering
In one of the largest and most complex government tender processes in Australia, Allens has advised Public Transport Victoria on the competitive tender for the operation of the myki ticketing syste ...
Allens advises Healthe Care on two major acquisitions
Allens has advised leading Australian private hospital operator Healthe Care Australia in relation to the acquisition of ASX-listed Pulse Health Limited and three hospitals in the Illawarra region ...
Allens advises Westpac on zipMoney investment
Allens has advised Westpac on its $40 million investment in listed Fintech zipMoney. The deal includes a $40 million equity investment, a grant of up to 9.8 million performance options and a ...
The High Court has its say on penalties
The high court handed down its decision in Paciocco v Australia and New Zealand banking group limited. ...
What's in a (biosimilar) name?
Because biosimilars and their reference biologic medicine are not identical whether compared to each other or even between biosimilars it is important to know which product has been used ...